ReviewAdvances in biological regulation2020
Thromboembolic events and Covid-19.
Review in Advances in biological regulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Associated thromboembolic events to the post COVID syndrome: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- A systematic review of thromboembolic complications and outcomes in hospitalised COVID-19 patients.BMC infectious diseases · 2024Pooled it
- Enduring coagulopathy and endothelial dysfunction in postacute COVID-19 syndrome.Blood vessels, thrombosis & hemostasis · 2026Article
- Fetal vascular malperfusion and other placental lesions in relation to maternal SARS-CoV-2 exposure: a case-control study.Frontiers in medicine · 2026Article
- Atrial Fibrillation in COVID-19: Mechanisms, Clinical Impact, and Monitoring Strategies.Biomedicines · 2025Review
- Adaptation of the WHO COVID-19 Clinical Progression Scale for Registry-Based Data: A Whole-Population Study in Sweden.Clinical epidemiology · 2025Article
- Clinical characteristics, treatment, and outcomes for elderly patients in a dedicated Covid-19 ward at a primary health care facility in western Norway: a retrospective observational study.BMC health services research · 2024Observational
- Article
- Ischemic Stroke in the Course of COVID-19 in a 16-Year-Old Boy.Journal of clinical medicine · 2023Article
- Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial.EClinicalMedicine · 2023Article
- A Comprehensive Review on Cardiovascular Complications of COVID-19: Unraveling the Link to Bacterial Endocarditis.Cureus · 2023Review
- Coagulation biomarkers and coronavirus disease 2019 phenotyping: a prospective cohort study.Thrombosis journal · 2023Article
- Pulmonary Thrombosis despite Therapeutic Anticoagulation in COVID-19 Pneumonia: A Case Report and Literature Review.Viruses · 2023Review
- Tomographic Findings in the Retina of Unvaccinated Patients with COVID Pneumonia: Prospective Longitudinal Study.International journal of environmental research and public health · 2023Article
- Prenatal and Neonatal Pulmonary Thrombosis as a Potential Complication of SARS-CoV-2 Infection in Late Pregnancy.International journal of molecular sciences · 2023Article
- Time Course of Coagulopathy Evaluated with Rotational Thromboelastometry in Patients with Severe Coronavirus Disease 2019.Internal medicine (Tokyo, Japan) · 2023Article
- Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients.Journal of clinical medicine · 2022Article
- Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine.The EPMA journal · 2022Review
- Early-stage COVID-19 pandemic observations on pulmonary embolism using nationwide multi-institutional data harvesting.NPJ digital medicine · 2022Article
- Real-Time Prediction of Mortality, Cardiac Arrest, and Thromboembolic Complications in Hospitalized Patients With COVID-19.JACC. Advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel Corona virus infection (Covid-19) first identified in China in December 2019 has rapidly progressed in pandemic leading to significant mortality and unprecedented challenge for healthcare systems. Although the clinical spectrum of Covid-19 is variable, acute respiratory failure and systemic coagulopathy are common in severe Covid-19 patients. Lung is an important target of the SARS-CoV-2 virus causing eventually acute respiratory distress syndrome associated to a thromboinflammatory state. The cytokinic storm, thromboinflammation and pulmonary tropism are the bedrock of tissue lesions responsible for acute respiratory failure and for prolonged infection that may lead to multiple organ failure and death. The thrombogenicity of this infectious disease is illustrated by the high frequency of thromboembolic events observed even in Covid-19 patients treated with anticoagulation. Increased D-Dimers, a biomarker reflecting activation of hemostasis and fibrinolysis, and low platelet count (thrombocytopenia) are associated with higher mortality in Covid-19 patients. In this review, we will summarize our current knowledge on the thromboembolic manifestations, the disturbed hemostatic parameters, and the thromboinflammatory conditions associated to Covid-19 and we will discuss the modalities of anticoagulant treatment or other potential antithrombotic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.